Free Trial

Eyenovia Q1 2023 Earnings Report

Eyenovia logo
$0.96 -0.15 (-13.50%)
As of 03:58 PM Eastern

Eyenovia EPS Results

Actual EPS
-$12.00
Consensus EPS
-$15.20
Beat/Miss
Beat by +$3.20
One Year Ago EPS
N/A

Eyenovia Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Eyenovia Announcement Details

Quarter
Q1 2023
Time
N/A

Conference Call Resources

Remove Ads

Eyenovia Earnings Headlines

Eyenovia enters non-binding LOI to effect reverse merger with Betaliq
Eyenovia Shares Drop 14% Amid Betaliq Merger Talks
Here’s How to Claim Your Stake in Elon’s Private Company, xAI
Even though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks like you… To partner with Elon on what he believes will be the biggest AI project of the century… Starting with as little as $500.
See More Eyenovia Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Eyenovia? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eyenovia and other key companies, straight to your email.

About Eyenovia

Eyenovia (NASDAQ:EYEN), an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

View Eyenovia Profile

More Earnings Resources from MarketBeat